Failed Verubecestat Trial May Call into Question Beta-amyloid Theory in Alzheimer’s, Study Suggests

Failed Verubecestat Trial May Call into Question Beta-amyloid Theory in Alzheimer’s, Study Suggests
Verubecestat (MK-8931) indeed failed to slow cognitive and functional decline in mild-to-moderate Alzheimer’s patients despite some reduction in beta-amyloid levels seen, final results of a Phase 2/3 study closed early by Merck for lack of efficacy confirmed. The researchers behind this study suggested these findings may call into question whether the amyloid hypothesis of Alzheimer’s is "correct," or whether it is relevant "once dementia is present." The findings were published in the New England Journal of Medicine, in a study titled “
Subscribe or to access all post and page content.